Once-weekly Insulin Icodec as Compared to Once-daily Basal Insulins: A Meta-analysis
Authors' conclusion
Once-weekly basal insulin icodec as compared to once-daily basal insulin analogs had a slight increase in the risk of overall hypoglycemia and weight gain, without any difference in severe hypoglycemia, with similar glycemic control (in terms of fasting plasma glucose, HbA1c, and TIR).
Study context
- Population
- Patients with T2D in different clinical settings7 RCTs
- Comparison
- Once-weekly insulin icodec vs once-daily basal insulins
- Outcome
- Glycaemic efficacy
Pooled result
As reported in the abstract
Each group vs nonicodecEstimated mean change in HbA1c, % (95% CI)
Icodec
−0.22(−0.35 to −0.10)
Each group vs nonicodecEstimated mean change in FPG, mg% (95% CI)
Icodec
−1.59(−9.26 to 6.08)
- Icodec
- estimated mean percentage increment in time in range (TIR) 4.24 % (95% CI 2.99–5.49)
Safety
| Outcome | Mantel-Haenszel RR (95% CI) | P value | |
|---|---|---|---|
| All hypoglycaemic events | 1.24 (1.02–1.50) | P = 0.03 | |
| Severe hypoglycaemia | 0.81 (0.31–2.08) | P is not significant | |
| 0.20.5125Mantel-Haenszel RR (log scale) |
| Outcome | Estimated mean increment (kg) (95% CI) |
|---|---|
| Weight | 0.64 (0.61–0.67) |
- All hypoglycaemic events — Increased incidence of all hypoglycaemia with icodec
- 24%
Original publication
Once-weekly Insulin Icodec as Compared to Once-daily Basal Insulins: A Meta-analysis. Endocr Pract. Published 19 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →